Kilitch Drugs (India) Ltd

Kilitch Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kilitch Drugs (India) Ltd

₹ 471 0.00%
21 May 10:05 a.m.
kilitch.com BSE: 524500 NSE: KILITCH
About

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]

Key Points

Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.

Website BSE NSE
  • Market Cap ₹ 757 Cr.
  • Current Price ₹ 471
  • High / Low ₹ 486 / 271
  • Stock P/E 30.4
  • Book Value ₹ 126
  • Dividend Yield 0.00 %
  • ROCE 17.3 %
  • ROE 13.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 161% CAGR over last 5 years
  • Company's median sales growth is 28.3% of last 10 years

Cons

  • Stock is trading at 3.75 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 9.07% over last 3 years.
  • Earnings include an other income of Rs.11.2 Cr.
  • Company has high debtors of 156 days.
  • Working capital days have increased from 115 days to 187 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
37 33 31 30 45 37 41 32 45 33 47 56 61
32 30 27 26 39 30 33 30 38 32 41 47 47
Operating Profit 5 3 4 4 6 6 9 2 7 2 6 9 15
OPM % 14% 10% 13% 13% 14% 17% 21% 7% 16% 5% 13% 16% 24%
0 1 0 1 1 1 0 3 0 3 5 2 2
Interest 1 1 2 1 1 2 2 2 1 2 0 1 2
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 4 3 2 2 5 5 7 3 5 2 10 8 14
Tax % 36% 40% -25% 31% 43% 33% 25% 38% 31% 93% 17% 32% 26%
2 2 2 2 3 3 5 2 4 0 9 6 10
EPS in Rs 1.86 1.34 1.56 1.52 2.28 2.16 2.95 1.81 2.23 0.83 5.36 3.71 6.47
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
108 19 21 27 51 82 53 68 114 140 154 198
95 21 25 28 45 75 53 63 104 122 130 167
Operating Profit 13 -2 -4 -1 6 7 0 5 10 18 24 31
OPM % 12% -9% -19% -2% 11% 9% 1% 8% 9% 13% 16% 16%
92 3 2 1 3 4 4 3 3 3 4 11
Interest 3 0 0 0 0 1 1 1 1 5 6 5
Depreciation 5 2 10 10 2 2 2 2 2 4 3 3
Profit before tax 97 -1 -12 -9 6 9 2 5 10 12 19 34
Tax % 22% -70% -4% -5% 16% 55% 48% 27% 35% 31% 30% 28%
76 -0 -11 -9 5 4 1 4 6 8 14 25
EPS in Rs 57.67 -0.22 -8.46 -6.72 3.75 2.49 0.54 2.37 4.73 6.71 9.08 16.60
Dividend Payout % 52% 0% 0% 0% 13% 20% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 26%
5 Years: 30%
3 Years: 20%
TTM: 28%
Compounded Profit Growth
10 Years: 42%
5 Years: 161%
3 Years: 67%
TTM: 97%
Stock Price CAGR
10 Years: 31%
5 Years: 39%
3 Years: 44%
1 Year: 37%
Return on Equity
10 Years: 3%
5 Years: 7%
3 Years: 9%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 13 13 13 13 14 15 15 15 16 16 16 16
Reserves 101 107 95 88 98 106 103 112 124 136 160 186
9 0 0 1 1 9 13 15 20 22 32 49
54 7 8 11 15 13 12 61 50 46 32 61
Total Liabilities 177 127 117 113 128 144 143 203 210 220 240 313
9 9 42 33 33 32 32 30 65 64 62 64
CWIP 0 0 0 1 3 20 30 65 3 4 6 47
Investments 138 72 49 53 56 53 52 60 71 62 72 72
30 46 25 26 35 38 30 47 71 90 100 129
Total Assets 177 127 117 113 128 144 143 203 210 220 240 313

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-29 -8 17 1 1 0 4 46 6 3 -0 18
41 -31 -20 -2 -4 -14 -10 -38 -15 8 -10 -40
-9 -0 0 -0 6 17 1 2 7 -1 9 13
Net Cash Flow 2 -39 -2 -0 2 3 -5 10 -2 10 -1 -9

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 51 243 286 196 148 86 109 122 132 142 149 156
Inventory Days 12 124 110 84 39 36 70 35 28 10 18 53
Days Payable 19 124 154 184 108 33 89 525 239 200 118 189
Cash Conversion Cycle 44 243 241 96 79 89 89 -367 -79 -48 50 20
Working Capital Days -114 197 237 124 100 79 108 -144 25 54 105 187
ROCE % 8% -10% -9% 5% 6% 1% 3% 6% 10% 13% 17%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
68.25% 68.24% 68.24% 68.24% 68.24% 69.23% 69.23% 69.23% 69.23% 69.23% 69.23% 69.23%
31.75% 31.75% 31.75% 31.75% 31.76% 30.78% 30.76% 30.77% 30.77% 30.77% 30.76% 30.77%
No. of Shareholders 9,2099,3809,4359,5229,5739,0029,0629,5259,6209,92010,1399,749

Documents

Announcements

Annual reports

Concalls